Related Experiment Video
Updated: Aug 25, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series
Amy Huber1, John D Huber, Robert B Skinner
1Department of Medicine, Division of Dermatology, University of Tennessee, Memphis, USA.
Background:
Imiquimod has been used for basal cell carcinomas (BCCs). This is the first open-label series using imiquimod for nodular BCC with Mohs surgery resection for confirmation of treatment.
Objective:
To evaluate the efficacy of topical imiquimod in patients with biopsy-proven nodular BCC.
Results:
After 12 weeks for three times a week application, treatment sites at week 15 were surgically excised using Mohs micrographic surgery. All 15 treatment subjects were clear of BCC. At the 18-month follow-up, no patients had recurrent tumor.
Conclusion:
Imiquimod 5% cream may be another treatment modality for nodular BCC.
